Adjuvant hormone therapy in patients undergoing high-intensity focused ultrasound therapy for locally advanced prostate cancer
https://doi.org/10.17650/1726-9776-2014-10-3-69-72
Abstract
Objective: to evaluate the efficiency and safety of using the luteinizing hormone releasing hormone leuprorelin with the Atrigel delivery system in doses of 7.5, 22.5, and 45 mg as an adjuvant regimen in high- and moderate-risk cancer patients who have received high-intensity focused ultrasound (HIFU) therapy.
Subjects and methods. Moderate- and high-risk locally advanced prostate cancer (PC) patients treated with HIFU (n = 28) and HIFU in combination with hormone therapy during 6 months (n = 31) were examined.
Results. The investigation has shown that leuprorelin acetate monotherapy used within 6 months after HIFU therapy can achieve the highest reduction in prostate-specific antigen levels and positively affect the symptoms of the disease. HIFU in combination with androgen deprivation substantially diminishes the clinical manifestations of the disease and improves quality of life in HIFU-treated patients with PC, by reducing the degree of infravesical obstruction (according to uroflowmetric findings and IPSS scores), and causes a decrease in prostate volume as compared to those who have undergone HIFU only. Treatment with leuprorelin having the Atrigel delivery system has demonstrated the low incidence of adverse reactions and good tolerability.
About the Authors
A. I. Neimark
Department of Urology and Nephrology, Altai State Medical University, Ministry of Health of Russia, Barnaul; Unit of Urology and Nephrology, Departmental Clinical Hospital at the Barnaul Station, OAO “RZhD”
Russian Federation
Russian Federation
M. A. Tachalov
Department of Urology and Nephrology, Altai State Medical University, Ministry of Health of Russia, Barnaul; Unit of Urology and Nephrology, Departmental Clinical Hospital at the Barnaul Station, OAO “RZhD”
Russian Federation
Russian Federation
B. A. Neimark
Department of Urology and Nephrology, Altai State Medical University, Ministry of Health of Russia, Barnaul; Unit of Urology and Nephrology, Departmental Clinical Hospital at the Barnaul Station, OAO “RZhD”
Russian Federation
Russian Federation
References
1. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН. 2009;20(3):52.
2. Шаплыгин Л.В., Соловов В.А., Воздвиженский М.О. и др. Высокоинтенсивная фокусированная ультразвуковая абляция в лечении гормонорезистентного локализованного и местно-распространенного рака предстательной железы. Сиб онкол журн 2012;2(50):18–21.
3. Митьков В.В., Васильева А.К., Митькова М.Д. Возможности ультразвуковой эластографии в диагностике рака предстательной железы. Ультразвуковая функциональная диагностика 2012;3:13–20.
4. Аляев Ю.Г., Крупинов Г.Е., Григорян В.А. и др. Высокоинтенсивный фокусированный ультразвук в лечении рака предстательной железы. Онкоурология 2007;2: 42–51.
5. Azzouz Н. HIFU: Local treatment of prostate cancer. EAU-EBU Update Series 2006;4:62–70.
6. Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2): 447–57.
7. Berges R. Eligard: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 2005;4:20–5.
8. Griffiths K. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502—8.
9. Алексеев Б.Я., Нюшко К.М. Гормональная терапия больных раком предстательной железы. Онкоурология 2007;3:57–62.
10. Chrisp P., Sorkin E.M. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991;1:487–509.
11. Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168: 1199–203.
Review
For citations:
Neimark A.I., Tachalov M.A., Neimark B.A. Adjuvant hormone therapy in patients undergoing high-intensity focused ultrasound therapy for locally advanced prostate cancer. Cancer Urology. 2014;10(3):69-72. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-3-69-72
Views:
903
Email this article 